Table 1.

Current recommendations for cervical cancer screening by the US Preventive Services Task Force (2012), American Cancer Society^a (2012), and/or American Congress of Obstetricians and Gynecologists (2016)

Average-risk Womenb
Age to begin	21 y
Method and intervals, by age	Ages 21–65 y: cytology every 3 y
	Or
	Ages 21–29 y: cytology every 3 y, then
	Ages 30–65 y: cytology plus hrHPV testing every 5 y
Age to end	65 yc
Higher-risk Women (ACOG 2016)
Infected with HIV	Age to begin: initiation of sexual activity, but no later than age 21 y
	Ages 21–29 y: cytology every year until 3 normal tests, then every 3 y
	Ages 30–65 y: cytology every year until 3 normal tests, then every 3 y, or: cytology plus hrHPV testing every 3 y
	Age to end: none
Immunocompromised for non-HIV reasons	Screening beginning at age 21 y, then as for women infected with HIV
In utero exposure to diethylstilbestrol	Annual cytology screening
Low-risk Women (ACOG 2016)
After total hysterectomy, no prior CIN2 +	Screening should not be performed

Abbreviation: HIV, human immunodeficiency virus.

^aWith the American Society of Colposcopy and Cervical Pathology and the American Society of Clinical Pathologists.

^bRecommendations apply to women with no prior diagnosis of CIN2 or a more severe lesion or cervical cancer (CIN21), women who are not immunocompromised (eg, HIV infected) and women with no in utero exposure to diethylstilbestrol.

^cOnly among women with 3 consecutive negative cytology results or 2 consecutive negative cytology plus hrHPV tests within 10 years before cessation of screening, with the most recent test performed within the last 5 years.